Aptevo director exercises 400 RSUs into common stock

Aptevo Therapeutics Inc. director Zsolt Harsanyi reported a derivative exercise involving restricted stock units.

Accepted by SEC EDGAR 08/10/2026 - 09:39 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Aptevo Therapeutics Inc. director Zsolt Harsanyi reported a derivative exercise involving restricted stock units. On August 6, 2026, 400 RSUs were converted on a one-for-one basis into 400 shares of common stock, with no per-share exercise price reported. The RSU position was reduced to 0, and direct ownership of common stock increased to 400 shares. The RSUs originated from a grant made on August 6, 2025, which vested on the first anniversary of the grant date.

Insider Trade Summary

400 shares exercised/converted

Exercise 2 txns

Insider Harsanyi Zsolt

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Unit F1, F2	400	$0.00	$0.00
Exercise	Common Stock F1	400	--	--

Holdings After Transaction: Restricted Stock Unit — 0 units (Direct); Common Stock — 400 shares (Direct)

Footnotes (2)

1. F1. Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis.
2. F2. On August 6, 2025, the reporting person was granted 7,200 (400 post-split) RSUs, vesting on the first anniversary of the date of grant.

Key Figures

RSUs exercised: 400 units Common shares acquired: 400 shares Common shares held after transaction: 400 shares +1 more

4 metrics

RSUs exercised 400 units Restricted Stock Units converted into common stock on August 6, 2026

Common shares acquired 400 shares Common stock received upon RSU conversion on August 6, 2026

Common shares held after transaction 400 shares Direct ownership of Aptevo common stock following the reported transactions

Original RSU grant (post-split) 400 units RSUs granted on August 6, 2025 (7,200 pre-split, 400 post-split), vesting after one year

Key Terms

Restricted Stock Unit, derivative security, par value per share, vests

4 terms

Restricted Stock Unit financial

"Restricted Stock Units ("RSUs") convert into common stock, $0.001 par"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

derivative security financial

"transaction_action": "derivative exercise/conversion""

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

par value per share financial

"common stock, $0.001 par value per share, of the Issuer"

Par value per share is the nominal, legally stated dollar amount assigned to a share in a company's charter or articles of incorporation. It determines the minimum legal capital recorded as 'stated capital' when shares are issued (the excess paid over par is recorded separately as additional paid‑in capital), but it is not the market price and often has no economic significance today; some shares are issued as 'no‑par' or with a very small par value depending on jurisdiction.

vests financial

"RSUs, vesting on the first anniversary of the date of grant"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Aptevo Therapeutics (APVO) director Zsolt Harsanyi report?

Director Zsolt Harsanyi reported exercising 400 restricted stock units into 400 shares of Aptevo common stock on August 6, 2026. This was recorded as an exercise or conversion of a derivative security.

How many Aptevo Therapeutics (APVO) RSUs did Zsolt Harsanyi convert and what did he receive?

He converted 400 restricted stock units into 400 shares of common stock of Aptevo Therapeutics. The RSUs converted on a one-for-one basis into common shares as described in the filing footnotes.

What are Zsolt Harsanyi’s Aptevo (APVO) holdings after this Form 4 transaction?

After the reported transactions, Zsolt Harsanyi directly holds 400 shares of Aptevo common stock and 0 restricted stock units from this grant. No additional derivative positions are listed in the filing’s derivative summary.

When were the Aptevo (APVO) RSUs originally granted to Zsolt Harsanyi?

The RSUs were granted on August 6, 2025, originally for 7,200 units (noted as 400 post-split) and were scheduled to vest on the first anniversary of the grant date, according to the footnote disclosure.

Did Aptevo (APVO) indicate a 10b5-1 trading plan for Zsolt Harsanyi’s Form 4 transaction?

The filing’s Rule 10b5-1 checkbox was not marked as an affirmative plan, and there is no footnote stating that the exercise occurred pursuant to a pre-arranged trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Harsanyi Zsolt

(Last) (First) (Middle)

2401 4TH AVENUE

SUITE 1050

(Street)

SEATTLE WASHINGTON 98121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Aptevo Therapeutics Inc. [ APVO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/06/2026		M		400	A	(1)	400	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	08/06/2026		M			400	(2)	(2)	Common Stock	400	$0	0	D

Explanation of Responses:

1. Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis.

2. On August 6, 2025, the reporting person was granted 7,200 (400 post-split) RSUs, vesting on the first anniversary of the date of grant.

	/s/ SoYoung Kwon, Attorney-in-Fact	08/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)